Yes Pre covid, there was a real scare among investors to buy Pharma scrips who are facing USFDA issues. Two things happened post covid.
- USFDA has mellowed down , albeit temporarily, in imposing regulatory requirements stringently.
- Indian Pharma companies have learned a lot on compliance of USFDA regulations and maintain documents on internal quality assurance procedures and the test data on the required format.
Indoco Remedies revenue is domestic dominant (60%) and hope they have set on strong growth path under the able leadership of Aditi Kare Panandikar.
Disc: Invested from lower levels and one of top 10 holdings and biased.